RxDoctor Payments Data

Maria Arguello, MD

Family Medicine · Margate, FLNPI 1417932344

Payments from drug & device makers

$3,766in general payments, 2019–2025

Across 227 payments — averaging $16.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$923
  • AstraZeneca$502
  • Amgen$400
  • Sanofi-aventis U.S. LLC$281
  • GSK$220
  • Amarin Pharma, Inc.$214
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$3,751100%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,766 in reported general payments places this provider in the 80th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$10,318
Medicare patients
45
Services billed
171

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol15$22,496
MounjaroTirzepatide14$20,460
Janumet XrSitagliptin Phos/Metformin Hcl11$11,671
Repatha SureclickEvolocumab13$7,288
SymbicortBudesonide/Formoterol Fumarate12$5,688
Nebivolol Hcl19$2,072
SynthroidLevothyroxine Sodium11$1,525
Raloxifene Hcl35$1,323
Rosuvastatin Calcium66$1,181
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide57$1,093
Gabapentin22$911
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$850
Levothyroxine Sodium79$724
Glipizide-MetforminGlipizide/Metformin Hcl12$551
Fluticasone Propionate27$484

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort$502$28,18427 claims
Lilly USA, LLCMounjaro$206$20,46014 claims
MerckJanumet Xr$109$11,67111 claims
AbbVieSynthroid$162$1,52511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Margate

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →